Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.41 |
| ▸ | CCR3 | P51677 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186456 | 0.93 | EPHX2 (0.46) | EPHX2RAF1CCR3HRH1KCNH2 | |
| SCHEMBL10184352 | 0.91 | EPHX2 (0.41) | EPHX2RAF1CCR3HRH1KCNH2 | |
| SCHEMBL10185322 | 0.90 | EPHX2 (0.43) | EPHX2DGAT1ACSL1 | |
| SCHEMBL10186415 | 0.90 | EPHX2 (0.47) | EPHX2RAF1PTGDR2NOTUMDGAT1 | |
| SCHEMBL10185364 | 0.89 | CCR3 (0.44) | CCR3HRH1KCNH2PTGDR2ACSL1 | |
| SCHEMBL10185105 | 0.89 | CCR3 (0.49) | CCR3HRH1KCNH2PTGDR2ACSL1 | |
| SCHEMBL10184358 | 0.88 | DRD4 (0.41) | EPHX2CCR3PTGDR2 | |
| SCHEMBL10185096 | 0.87 | ACSL1 (0.43) | EPHX2PTGDR2DGAT1ACSL1 | |
| SCHEMBL10186162 | 0.87 | CCR3 (0.44) | CCR3HRH1KCNH2PTGDR2DGAT1 | |
| SCHEMBL10186165 | 0.86 | CCR3 (0.43) | CCR3HRH1PTGDR2DGAT1ACSL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | EPHX2 1718/4885RAF1 4751/4885CCR3 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.